bimatoprost implant Durysta
Selected indexed studies
- Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation. (Drug Des Devel Ther, 2025) [PMID:39906697]
- Durysta - a bimatoprost implant for glaucoma. (Med Lett Drugs Ther, 2020) [PMID:32728012]
- Bimatoprost Implant: First Approval. (Drugs Aging, 2020) [PMID:32447639]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Bimatoprost Implant: First Approval. (2020) pubmed
- Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation. (2025) pubmed
- Intracameral sustained release bimatoprost implants (Durysta). (2022) pubmed
- Newer advances in medical management of glaucoma. (2022) pubmed
- Durysta - a bimatoprost implant for glaucoma. (2020) pubmed
- New treatments for glaucoma. (2025) pubmed
- Bimatoprost. (2006) pubmed
- Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies. (2023) pubmed
- Mobile bimatoprost implant requiring surgical extraction. (2024) pubmed
- Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice. (2025) pubmed